In a landmark achievement for UK higher education and cancer research, scientists from the University of Edinburgh and University College London (UCL) have published groundbreaking results in Nature detailing a single-dose gene therapy that completely eradicated aggressive glioblastoma tumours in preclinical models. This innovation, developed through Trogenix—a spinout company co-founded by Professor Steven Pollard from Edinburgh—promises to transform treatment for one of the deadliest brain cancers, highlighting the pivotal role of British universities in translating basic research into potential cures.

Glioblastoma multiforme (GBM), the most common and aggressive primary brain tumour in adults, claims around 3,200 lives annually in the UK alone, with a dismal five-year survival rate of less than 5%—just 160 patients survive long-term. Standard treatments like surgery, radiotherapy, and chemotherapy offer median survival of 12-15 months, often failing due to tumour heterogeneity, infiltration into healthy brain tissue, and resistance driven by glioblastoma stem cells (GSCs). The Trogenix team's approach addresses these core challenges head-on, using precision genetic engineering rooted in stem cell biology expertise from Edinburgh's Centre for Regenerative Medicine and UCL's contributions to immunotherapy.

🧬 The Science Behind Synthetic Super-Enhancers

The therapy hinges on Synthetic Super-Enhancers (SSEs), engineered DNA constructs that act as highly selective 'switches' activated only in GSCs. These cells, marked by overexpression of transcription factors SOX2 and SOX9, drive tumour initiation, therapy resistance, and recurrence. SSEs assemble validated enhancer fragments into arrays that recruit SOX2/SOX9 multimers, amplifying expression exclusively in diseased cells while remaining silent in healthy neurons, microglia, or astrocytes.

Delivered via adeno-associated virus serotype 1 (AAV1)—chosen for its neurotropism and safety profile^®—the SSEs drive dual payloads: HSV-thymidine kinase (HSV-TK), a 'suicide gene' that converts systemic ganciclovir (GCV) into a toxic metabolite killing transduced cells, and interleukin-12 (IL-12), an immunomodulator that recruits and activates T cells and natural killer cells. This 'Trojan horse' strategy evades immune detection, infiltrates the tumour, and triggers both direct cytotoxicity and adaptive immunity.

Step-by-step process:

• AAV1 injects SSE-payload into the tumour via convection-enhanced delivery.
• SSE activates only in SOX2/9-high GSCs, expressing HSV-TK and IL-12.
• GCV administration converts to toxin, lysing cancer cells and releasing antigens.
• IL-12 sustains inflammation, priming memory T cells for durable protection.

Preclinical Triumph: 83% Complete Remission

In a syngeneic orthotopic mouse model mimicking human GBM (Nf1/P53-deficient, EGFRvIII-amplified), a single intratumoral AAV1-SSE-7 dose (3×10¹⁰ vg) plus 20 days of GCV eradicated tumours in 83% (20/24) of treated mice within 2-3 weeks, versus rapid death in controls (median survival 12 days). No recurrence over 11 months, with re-challenge experiments showing full immunity (0/10 regrowth vs. 10/10 in naïve mice). Transduction hit ~20% of tumour cells, sufficient for bystander killing and immune priming.

Safety shone through: no weight loss, neurological deficits, or off-target effects, unlike CMV-promoter controls causing rapid toxicity. Human validation used patient-derived GSC lines (7 subtypes) and ex vivo GBM slices, confirming SSE selectivity (90% SOX2 co-expression in tumours, minimal in margins/normal cortex). Single-cell RNA-seq (270k cells) revealed SSE integration of neurodevelopmental programs without subtype bias.Read the full Nature paper.

Key stats:

• Tumour clearance: 83% complete, durable >11 months.
• Immune shifts: ↑CD8⁺ T/NK cells, ↓Tregs/MDSCs (p<0.001).
• Selectivity: >100-fold GSC vs. normal cells.

Edinburgh and UCL: Pillars of UK Brain Cancer Innovation

The University of Edinburgh's Institute for Regeneration and Repair, home to Pollard's lab, pioneered GSC models and enhancer engineering over a decade, funded by Cancer Research UK (CRUK) and BBSRC. UCL's Immune Regulation Group contributed IL-12 expertise, blending synthetic biology with immunotherapy. Trogenix, spun out in 2023 via Edinburgh Innovations, exemplifies UK uni-commercial translation, raising £70M Series A (Oct 2025) from IQ Capital, CRUK Horizons, Lilly Ventures—UK's largest CRUK investment.

This collaboration underscores Scotland's CRUK Centres of Excellence and England's UCL Cancer Institute, fostering interdisciplinary hubs. Edinburgh's mammalian synthetic biology centre enabled SSE design, while UCL advanced payload optimization.

Professor Steven Pollard: Visionary Behind the Breakthrough

Professor Pollard, Chair of Stem Cell and Cancer Biology at Edinburgh, co-founded Trogenix as CSO. His lab decoded GBM stemness via SOX networks, shifting paradigms from bulk tumour to GSC targeting. Pollard: "We've achieved what seemed impossible—complete elimination with one dose, no toxicity, lasting immunity." Over 100 publications, Pollard's work bridges development, cancer, and gene therapy.

Team includes Ute Koeber (lead author, now IQVIA), Neza Alfazema, with UCL's Sergio Quezada on immunology.

From Bench to Bedside: ADePT Trial Looms

Trogenix's Phase I/II ADePT trial (NCT07346144) starts Q2 2026, testing AAV1-SSE dual-payload safety/dosing in recurrent GBM. First-in-human via intratumoral injection post-resection, monitoring efficacy signals. CRUK's Dr Iain Foulkes hailed it as foundational for better options, given GBM's unmet need.

Regulatory momentum: AAV1's established profile (Zolgensma) eases path; SSE novelty demands Phase I focus.

Transforming GBM Treatment Landscape

Current GBM therapy (Stupp protocol) yields 15-month median survival; SSE therapy could enable cures via one-time dosing, reducing morbidity. Immune memory counters recurrence (90% within 2 years). Platform versatility targets other SOX-driven cancers (e.g., prostate, lung).

UK impact: Positions unis as biotech hubs, attracting talent/funding amid post-Brexit challenges.

Challenges: Heterogeneity, Delivery, Immunity

GBM's blood-brain barrier hampers drugs; AAV convection bypasses. GSC plasticity addressed by SOX core circuitry. Immune-cold microenvironment pierced by IL-12. Human translation risks: immunogenicity, dose optimization—trial mitigators.

• Advantages over CAR-T: Off-shelf, local delivery.
• Vs. checkpoint inhibitors: Tumour-selective activation.

Boosting UK Higher Ed Research Ecosystem

Edinburgh/UCL exemplify CRUK-funded excellence, spinouts like Trogenix (£70M raised) driving GDP. UK ranks top-5 globally in biotech; SSE advances synthetic biology, aligning UKRI priorities. Careers flourish: 1000s research jobs in gene therapy.Explore Trogenix careers.

Stats: UK brain cancer R&D £50M+/year; Pollard lab trains PhDs/postdocs in cutting-edge CRISPR/omics.

Future Horizons: Beyond GBM

SSE platform expandable to SOX-high tumours; regenerative apps (e.g., stem cell control). Trials could redefine solid tumour paradigms, crediting UK unis' foundational work. Pollard envisions 'curative one-and-done' therapies revolutionizing oncology.

For UK higher ed: Reinforces Edinburgh's regenerative medicine leadership, UCL's immunotherapy prowess, inspiring next-gen researchers amid funding squeezes.

Photo by tommao wang on Unsplash

This Edinburgh-UCL triumph spotlights UK academia's global impact, paving curative paths for GBM patients while opening research avenues. As ADePT advances, watch for recruitment at top unis.